Interleukin Genetics – About the Company
Interleukin Genetics (OTCQB: ILIU) is a genetic diagnostics company that develops and markets tests that help patients improve health through preventative measures. The Company is primarily focused on the commercialization of PerioPredict, a genetic test that identifies variations in the IL-1 gene. The test recommends certain patients to receive additional preventative dental visits, which have been shown to reduce the risk of inflammatory conditions such as periodontitis, diabetes, and cardiovascular disease. Studies have indicated a clear pharmacoeconomic benefit associated with this preventive treatment. The current strategy for commercialization is targeting employers and large insurance providers who seek to benefit from PerioPredict by focusing individuals at high risk for chronic inflammatory diseases and thereby lowering medical costs for the entire group.